CATO vs RCUS vs AGEN vs PLCE vs NKTR

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate Arcus Biosciences, Inc. (RCUS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -95. 8% for The Children's Place, Inc. (PLCE). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Cato Corporation (CATO) is the lower-risk stock at 0.

88β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 208% more volatile than CATO relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PLCE leads at 1. 2% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AGEN: 95.

5% to $7. 33.

In this comparison, CATO (18.

7% yield) pays a dividend. RCUS, AGEN, PLCE, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Cato Corporation (CATO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

88), 18. 7% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CATO: -72. 3%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CATO (Consumer Cyclical) and RCUS (Healthcare) and AGEN (Healthcare) and PLCE (Consumer Cyclical) and NKTR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CATO is a small-cap income-oriented stock; RCUS is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; PLCE is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock. CATO pays a dividend while RCUS, AGEN, PLCE, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.